Ronald E. Bruehlman Joins GoodRx Board of Directors

GDRX 10.28.2024

Full Press ReleaseSEC FilingsOur GDRX Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Scott Wagner Joins GoodRx Board of Directors
  • 01.21.2025 - Steven Valiquette
  • 01.15.2025 - Wendy Barnes

Recent Filings

  • 01.22.2025 - 8-K Current report
  • 01.15.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.08.2025 - 3 Initial statement of beneficial ownership of securities
PDF Version

IQVIA CFO brings 39 years of healthcare and finance expertise toGoodRx

SANTA MONICA, Calif.--(BUSINESS WIRE)--Oct. 28, 2024--GoodRx Holdings, Inc.(Nasdaq: GDRX) ("we," "us," "our," “GoodRx” or the “Company”), the leading prescription savings platform in theU.S., today announced the election ofRonald E. Bruehlmanto its Board of Directors, effectiveNovember 8, 2024.Mr. Bruehlmanbrings toGoodRx39 years of finance experience in the healthcare services, industrial and petroleum industries. He currently serves as Chief Financial Officer of IQVIA, a global provider of advanced analytics, technology solutions, and contract research. Prior to IQVIA, he served as CFO ofIMS Healthand had a 23-year career at United Technologies Corporation, where he held multiple senior finance leadership roles of increasing responsibility.Mr. Bruehlmanpreviously served on the board of directors ofAtotech Ltd., Q-Squared Solutions, and Clipper Windpower.

"We are thrilled to welcomeMr. Bruehlmanto the GoodRx Board. His extensive expertise leading financial strategies for public and private healthcare and technology companies is a perfect match forGoodRxas we navigate the complex healthcare market," saidTrevor Bezdek,GoodRxco-founder and Chairman of the Board. "Mr. Bruehlman’s deep financial insight and strategic acumen will be critical as we continue to focus on sustainable and profitable revenue growth, aiming to enhance affordability and access to prescription medications across the country. His leadership will ensure the highest standards of financial management and strategic risk assessment as we drive forward our mission.”

Mr. Bruehlmanwill also serve as the chairperson of the Board’sAudit and Risk Committee, following Julie Bradley’s resignation as a member of GoodRx’s Board of Directors effective onNovember 8, 2024.

AboutGoodRx

GoodRxis the leading prescription savings platform in theU.S.Trusted by more than 25 million consumers and 750,000 healthcare professionals annually,GoodRxprovides access to savings and affordability options for generic and brand-name medications at more than 70,000 pharmacies nationwide, as well as comprehensive healthcare research and information. Since 2011,GoodRxhas helped consumers save over$75 billionon the cost of their prescriptions.

GoodRxperiodically posts information that may be important to investors on its investor relations website athttps://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with theSecurities and Exchange Commission(“SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the anticipated contributions fromRonald E. Bruehlmanin his directorship and expected benefits to the Company and our Board. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to attract and retain talent and the important factors discussed under the caption “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year endedDecember 31, 2023, and our other filings with theSEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241028840743/en/

Investor Contactir@goodrx.com

Media Contactpress@goodrx.com

Source:GoodRx

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com